Pancreatitis Risk
29 articles on Pancreatitis Risk, researched and written by the Shotlee Editorial Team from primary sources.
Beyond BMI: Hidden Health Reasons Doctors May Decline Mounjaro or Wegovy
While BMI is a primary factor, a range of underlying health conditions and personal histories can lead to a doctor declining a prescription for popular weight loss medications like Mounjaro and Wegovy. Understanding these criteria is vital before seeking treatment.
7 min read
GLP-1 Agonists: Age Limits & Serious Risks of Weight Loss Drugs
This comprehensive guide delves into the critical considerations surrounding GLP-1 agonists for weight loss, addressing common concerns about age limits, potential risks, and practical advice for patients.
7 min read
Generic Ozempic Semaglutide Gets Tentative USFDA Approval; OneSource CDMO Par...
A generic version of Ozempic semaglutide has received tentative USFDA approval, marking a key step toward affordable GLP-1 therapy. Orbicular spearheaded product development, partnering with OneSource Specialty Pharma as the CDMO for reliable U.S. market manufacturing. This collaboration promises steady commercial supply from an FDA-approved site.
5 min read
Adele's Before & After Pics Highlight 100-Pound Weight Loss
Musician Adele transformed her body in 2020, losing 100 pounds via exercise and a healthy diet amid rising anxiety after her 2019 divorce. Before Ozempic and Mounjaro gained popularity, she focused on building physical and mental strength. Her before-and-after photos and candid interviews reveal a powerful story of self-improvement.
5 min read
Quitting GLP-1s Like Ozempic? Many Plan to Restart Despite Risks
Many patients start GLP-1 medications like Ozempic and Zepbound for obesity but quit within a year, with fewer than one in four remaining on treatment. Shockingly, 74% of those who stop plan to restart, despite experts warning against this cycling approach. This guide explores the data, risks like muscle loss, and what it means for your health.
5 min read
Ozempic Isn't a Magic Fix: Semaglutide Risks in India
Semaglutide injections like Ozempic have arrived in India at low prices, exciting millions with diabetes and rising obesity. But experts like Dr. Gagandeep Singh caution it's no magic fix—weight returns upon stopping, muscle loss is common, and misuse risks malnutrition. Understand the real story behind these GLP-1 weight loss injections.
6 min read
Eli Lilly Eyes India Rollout for Oral Obesity Drug Orforglipron
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
5 min read
Genetic Variations Linked to GLP-1 Weight Loss, Side Effects
New research from 23andMe reveals genetic variants in GLP1R that boost weight loss from GLP-1 drugs by up to 3.3 pounds. GIPR mutations increase vomiting risk on tirzepatide. Meanwhile, semaglutide's heart benefits appear independent of weight loss, opening doors to precision dosing.
5 min read
Cheaper Generic Semaglutide in India: Experts Warn Against Quick-Fix Use
Cheaper generic semaglutide is transforming access to weight loss and diabetes treatment in India, priced at just Rs750 per weekly injection. However, experts caution against 'quick-fix' use without medical oversight, highlighting risks like 40% muscle loss from lean mass. Discover clinical evidence from STEP-1 and SELECT trials and why structured care is essential.
5 min read
Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs
Matthew Gallagher, a 41-year-old LA entrepreneur, turned $20,000 into a nearly $2 billion telehealth empire with AI alone. Medvi sells GLP-1 drugs like Ozempic at $300 versus $1,000 retail, serving 250,000 customers. But rapid growth sparks debates on legality and fake ads.
5 min read
Eli Lilly Turns to AI After GLP-1 Boom for Next Growth
Eli Lilly is leveraging artificial intelligence to find its next big breakthrough after the GLP-1 boom transformed diabetes and obesity treatment. With rivals like Novo Nordisk in hot pursuit, Lilly's AI investments promise faster drug discovery and smarter clinical trials. This strategic shift could diversify revenue and bring new options to patients sooner.
6 min read
Lost My Daughter's Weight on Mounjaro: Rethinking Body Image Talks
After shedding 48kg on Mounjaro—matching her slim teenage daughter Lily's weight—Ariane Sherine reevaluated her approach to body talk. Once plagued by disordered eating, she now prioritizes her daughter's happiness over scales. This personal story highlights Mounjaro's transformative power and body positivity lessons.
5 min read
GLP-1 Therapies: Risks and Rewards Across Conditions
GLP-1 therapies, including Ozempic (semaglutide) and Mounjaro (tirzepatide), have evolved from diabetes treatments to versatile options for weight management and cardiovascular health. While offering significant benefits like reduced appetite and vascular protection, they come with gastrointestinal side effects and rare serious risks. This guide evaluates their risks and rewards across conditions.
5 min read
Telangana DCA Warns Against Unsupervised Semaglutide Use Amid Weight Loss Demand
The Telangana Drugs Control Administration (DCA) has issued a strong warning against unsupervised use of semaglutide, a popular GLP-1 drug for weight loss and Type-2 diabetes management. With generics now available from Sun Pharma, Dr. Reddy's, Zydus, and Glenmark following patent expiry, demand is surging—but so are risks like acute pancreatitis and kidney injury. Always consult a doctor for proper assessment and prescription.
5 min read
Should You Take GLP-1 Drugs for Longevity?
A quote from The Economist's Style Guide warns against calling anything a panacea—yet GLP-1 drugs for type 2 diabetes and obesity are now eyed by healthy individuals for longevity. Is their time as a miracle cure finally here? This guide weighs the excitement against expert caution and real-world considerations.
4 min read
Weight Loss Injections Side Effects Affect 1 in 10 Users
Weight loss injections such as Mounjaro and Wegovy, popular GLP-1 inhibitors, come with side effects impacting one in 10 users, primarily digestive issues like nausea and diarrhea. The British Heart Foundation highlights risks including pancreatitis, vision loss, and nutritional deficiencies. Understanding these helps patients manage treatment safely.
5 min read
Microdosing Ozempic: 67-Year-Old Bobbi Parker-Hall Enjoys Multiple Orgasms
At 67, Bobbi Parker-Hall microdoses Ozempic not for dramatic weight loss, but for metabolic stability and surprising intimacy benefits like multiple orgasms. She shares how low-dose semaglutide, paired with strength training, keeps her lean and vibrant post-menopause. Here's what her story reveals about this trending approach.
5 min read
Burn Slim Exposed: Real Users Reveal GLP-1 Mimetic Effects
Burn Slim Capsules are gaining attention as a natural GLP-1 mimetic alternative to prescription drugs like semaglutide. Real users report dramatic appetite changes, consistent fat loss up to 22 pounds in 12 weeks, and sustained results without muscle loss or loose skin. Backed by studies on its four key ingredients, this guide exposes the science and user truths.
6 min read
AIOCD Urges Chemists: Sell GLP-1 Drugs Only on Valid Prescription Amid Demand...
With surging demand for GLP-1 drugs in India, the All India Organisation of Chemists and Druggists (AIOCD) has issued a strict reminder to its 12.4 lakh members: sell obesity and diabetic GLP-1 medications, including injectables, only against valid prescriptions from qualified practitioners. This comes as pharma giants like Eli Lilly promote awareness for proper treatment. Understand the implications for patients seeking Tirzepatide brands like Mounjaro and Zepbound.
4 min read
Donna Kelce Denies Weight-Loss Drugs, Credits Intermittent Fasting
Donna Kelce, mother of NFL stars Travis and Jason, is clapping back at online speculation that her slimmer figure on The Traitors came from weight-loss drugs like Ozempic. The 73-year-old reveals she lost about 30 pounds over a year through intermittent fasting alone. Her story highlights natural paths to metabolic health amid GLP-1 hype.
5 min read
Tirzepatide Activates Brown Fat to Burn Calories, Mouse Study Shows
Tirzepatide doesn't just curb hunger—it may directly rev up fat-burning brown adipose tissue, according to a groundbreaking mouse study. Researchers separated its metabolic effects from simple calorie restriction, uncovering benefits for energy expenditure and blood glucose control. This could pave the way for more effective obesity therapies.
6 min read
Study: Ozempic, Wegovy NAION Risk Twofold Higher vs. SGLT2i Drugs
New research from Veterans' Affairs shows Ozempic and Wegovy users face double the risk of NAION—a serious vision loss condition—compared to SGLT2i drugs. Published in JAMA Ophthalmology, the study urges doctors to warn patients about potential permanent blindness from semaglutide-based GLP-1 medications. As lawsuits mount, understand the implications for diabetes and weight management.
5 min read
Mum Dies Days After £20 Unregulated Skinny Jab: Family Demands Change
A mother's heartbreaking death after a cheap black market 'skinny jab' has sparked a family's campaign for tougher regulations. Karen McGonigal passed away days after receiving unregulated semaglutide at a beauty salon. Now, her daughters are urging the government to act before more lives are lost.
6 min read
Eli Lilly Shares Face Pressure Amid GLP-1 Market Shifts
Eli Lilly posted blockbuster Q4 2025 results with $19.29B revenue, yet shares near $1,020 face selling pressure from compounded semaglutide competition and government pricing initiatives. Hims & Hers' $49 pill undercuts Zepbound's $299 intro dose, signaling shifts in the GLP-1 market. Investors eye Orforglipron's FDA decision amid pipeline cuts.
5 min read
Ozempic Rebound: Weight Regain After Stopping GLP-1 Drugs
GLP-1 drugs like Ozempic promise dramatic weight loss, but what happens when you stop? Studies reveal rapid regain—often half or more of lost weight—due to rebound hunger and metabolic shifts. This guide breaks down the mechanisms, evidence, and sustainable strategies.
5 min read
GLP-1 Warning: Pancreatitis Risk with Ozempic, Wegovy, Mounjaro
The MHRA has updated warnings for GLP-1 medications such as Ozempic, Wegovy, and Mounjaro, highlighting a rare but serious risk of acute pancreatitis. With 1.6 million UK users in the past year, knowing the symptoms of severe abdominal pain radiating to the back is crucial. This guide breaks down the science, risks, and steps for safe use.
4 min read
GLP-1 Drugs Pancreatitis Risk: Symptoms & What to Know
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but recent label updates highlight a small yet serious risk of acute pancreatitis. This guide breaks down the symptoms, science, and steps to stay safe. Know the signs to protect your health.
4 min read
GLP-1 Pancreatitis Risk: MHRA Warning and Patient Guide
The UK's MHRA has updated guidance on a small but serious risk of acute pancreatitis linked to popular GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro. With over 1.6 million users, understanding symptoms and reporting is crucial. This guide breaks down the latest data, risks, and management strategies.
4 min read
Semaglutide Generics: Spain Cuts Ozempic Costs
Ozempic and Wegovy have transformed weight management, but high costs limit access. A Spanish company is now manufacturing generic semaglutide, poised to slash prices as patents expire. This guide explores the implications for patients seeking affordable GLP-1 therapy.
4 min read